PURPOSE: Animal milk fat globule-EGF factor 8 (MFG-E8) has been shown to be beneficial in attenuating the inflammatory response in sepsis. In this study, we examined the effect of recombinant human MFG-E8 (rhMFG-E8) in an animal model of sepsis in an effort to develop it as a potential therapy against sepsis in humans. METHODS: Rats were subjected to sepsis by cecal ligation and puncture (CLP), and at 5 h post-CLP, they were given different doses of rhMFG-E8 (20, 40, 80, 160 μg/kg BW) in normal saline. At 20 h post-CLP, samples were collected for further analysis. A 10-day survival study was also performed. RESULTS: At 20 h after CLP, organ injury indicators, serum IL-6 and TNF-α, and plasma HMGB-1 levels were significantly increased as compared to sham-operated animals. Treatment with 20 μg/kg rhMFG-E8 significantly reduced these levels. With higher doses, further reductions in AST and ALT (59-62%), creatinine (65-68%), and lactate (46-57%), and serum IL-6 and TNF-α were obtained. The 160 μg/kg dose produced the greatest reduction in serum TNF-α. With treatment with 20 μg/kg rhMFG-E8, HMGB-1 levels decreased by 80%, returning back to sham values. In a 10-day survival study, vehicle-treated animals produced a 36% survival rate, while rhMFG-E8 significantly improved the survival rate to 68-72%. Treatment with increasing doses of rhMFG-E8 significantly reduced the number of apoptotic cells detected and markedly attenuated the tissue damages observed in the lungs. CONCLUSIONS: These data suggest that recombinant human MFG-E8 is beneficial in ameliorating sepsis in an animal model of sepsis.
PURPOSE: Animal milk fat globule-EGF factor 8 (MFG-E8) has been shown to be beneficial in attenuating the inflammatory response in sepsis. In this study, we examined the effect of recombinant humanMFG-E8 (rhMFG-E8) in an animal model of sepsis in an effort to develop it as a potential therapy against sepsis in humans. METHODS:Rats were subjected to sepsis by cecal ligation and puncture (CLP), and at 5 h post-CLP, they were given different doses of rhMFG-E8 (20, 40, 80, 160 μg/kg BW) in normal saline. At 20 h post-CLP, samples were collected for further analysis. A 10-day survival study was also performed. RESULTS: At 20 h after CLP, organ injury indicators, serum IL-6 and TNF-α, and plasma HMGB-1 levels were significantly increased as compared to sham-operated animals. Treatment with 20 μg/kg rhMFG-E8 significantly reduced these levels. With higher doses, further reductions in AST and ALT (59-62%), creatinine (65-68%), and lactate (46-57%), and serum IL-6 and TNF-α were obtained. The 160 μg/kg dose produced the greatest reduction in serum TNF-α. With treatment with 20 μg/kg rhMFG-E8, HMGB-1 levels decreased by 80%, returning back to sham values. In a 10-day survival study, vehicle-treated animals produced a 36% survival rate, while rhMFG-E8 significantly improved the survival rate to 68-72%. Treatment with increasing doses of rhMFG-E8 significantly reduced the number of apoptotic cells detected and markedly attenuated the tissue damages observed in the lungs. CONCLUSIONS: These data suggest that recombinant humanMFG-E8 is beneficial in ameliorating sepsis in an animal model of sepsis.
Authors: Markus S Huber-Lang; Ellen M Younkin; J Vidya Sarma; Stephanie R McGuire; Kristina T Lu; Ren Feng Guo; Vaishalee A Padgaonkar; John T Curnutte; Richard Erickson; Peter A Ward Journal: J Immunol Date: 2002-09-15 Impact factor: 5.422
Authors: Mitchell M Levy; R Phillip Dellinger; Sean R Townsend; Walter T Linde-Zwirble; John C Marshall; Julian Bion; Christa Schorr; Antonio Artigas; Graham Ramsay; Richard Beale; Margaret M Parker; Herwig Gerlach; Konrad Reinhart; Eliezer Silva; Maurene Harvey; Susan Regan; Derek C Angus Journal: Crit Care Med Date: 2010-02 Impact factor: 7.598
Authors: R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy Journal: Intensive Care Med Date: 2004-03-03 Impact factor: 17.440
Authors: Masahisa Jinushi; Yukoh Nakazaki; Daniel R Carrasco; Dobrin Draganov; Nicholas Souders; Matthew Johnson; Martin C Mihm; Glenn Dranoff Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Charles L Sprung; Janice L Zimmerman; Michael D Christian; Gavin M Joynt; John L Hick; Bruce Taylor; Guy A Richards; Christian Sandrock; Robert Cohen; Bruria Adini Journal: Intensive Care Med Date: 2010-02-05 Impact factor: 17.440
Authors: Laura W Hansen; Weng Lang Yang; Alexandra C Bolognese; Asha Jacob; Tracy Chen; Jose M Prince; Jeffrey M Nicastro; Gene F Coppa; Ping Wang Journal: Surgery Date: 2017-03-23 Impact factor: 3.982
Authors: Fangming Zhang; Kavin G Shah; Lei Qi; Rongqian Wu; Rafael Barrera; Jeffrey Nicastro; Gene F Coppa; Ping Wang Journal: J Trauma Acute Care Surg Date: 2012-04 Impact factor: 3.313
Authors: Jan G D'Haese; Ihsan Ekin Demir; Timo Kehl; Jannik Winckler; Nathalia A Giese; Frank Bergmann; Thomas Giese; Markus W Büchler; Helmut Friess; Mark Hartel; Güralp O Ceyhan Journal: BMC Gastroenterol Date: 2013-01-16 Impact factor: 3.067